Drugs & Pharmacotherapy in Diabetes
Evidence-based clinical evaluations, cardiovascular and renal outcome studies, and therapeutic innovations in incretins, SGLT-2 inhibitors, and modern insulins.
Advancing Pharmacological Care
Our clinical research team investigates efficacy, safety profiles, and real-world outcomes of novel antidiabetic agents to tailor therapies to individual metabolic phenotypes.
GLP-1 Receptor Agonists
Prospective trials on once-weekly and daily GLP-1 RAs (Dulaglutide, Semaglutide), highlighting potent glucose control, weight reduction, and non-alcoholic fatty liver disease (NAFLD) resolution.
Dual GIP / GLP-1 Co-Agonists
Investigating dual incretin agonists (Tirzepatide) in Asian Indian populations, evaluating near-normoglycemic remission rates and profound visceral adiposity reductions.
SGLT-2 Inhibitors & Cardiorenal Care
Real-world longitudinal registry studies analyzing cardiorenal protection, heart failure mitigation, and glomerular filtration rate (eGFR) preservation with SGLT-2 inhibitors.
Once-Weekly Basal Insulins
Participating in landmark global trials of novel once-weekly basal insulin analogues (Insulin Icodec and Efsitora alfa), improving injection adherence and patient quality of life.
Combination Therapies
Investigating early fixed-dose and individualized combination therapies to achieve durable beta-cell preservation and early target glycemic attainment.
South Asian Guidelines
Translating clinical trial outcomes into evidence-based consensus guidelines tailored specifically for the unique metabolic, dietary, and genetic profiles of South Asian patients.
Explore Pharmacotherapy Publications
Browse our peer-reviewed publications on GLP-1 RAs, SGLT-2 inhibitors, insulin therapies, and clinical pharmacology indexed in PubMed, Scopus, and international databases.
Our Hospital & Research Branches
Accessible, world-class comprehensive diabetes care and clinical research across 5 strategic locations.